Biological heterogeneity of er‐positive breast cancers in the post‐menopausal population

  title={Biological heterogeneity of er‐positive breast cancers in the post‐menopausal population},
  author={Sylvie Romain and Olivier L Chinot and O. Guirou and M. J. Soulliere and P. M. Martin},
  journal={International Journal of Cancer},
In the natural history of post‐menopausal patients with primary breast cancer, high estrogen receptor levels (ER) have been associated with a poor recurrence‐free survival. The purpose of this study was to investigate whether there are any biological intratumoral characteristics to support this puzzling clinical observation. In a population of 542 post‐menopausal, primary‐breast‐cancer patients, 3 normal distributions fitted into the frequency distribution curve of the logarithmically… 

Increases in estrogen receptor‐α concentration in breast cancer cells promote serine 118/104/106‐independent AF‐1 transactivation and growth in the absence of estrogen

The results suggest that elevated levels of ERα in breast cancer cells can result in activation of receptor transcriptional function in a manner distinct from classical mechanisms that involve ligand binding or growth factor‐induced phosphorylation, and describe a potential mechanism whereby increases in ERα concentration may provide a proliferative advantage by augmenting ERα function regardless of ligand status.

EGFR in Early Non-small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial

The first clinical trial exploring the use of an EGFR TKI in early NSCLC is generated, characterizing for the first time the histopathological and signalling responses to these agents with an evidence of a potential novel mechanism of resistance.

Intratumor heterogeneity of biomarker expression in breast carcinomas

This work examined immunohistochemically the expression of HER-2neu, epidermal growth factor receptor (EGFR), Bcl-2, p53, and proliferating cell nuclear antigen in 30 breast carcinomas using archived, paraffin embedded tissue and determined the extent of intratumor heterogeneity.

Intratumoral Heterogeneity of Immunohistochemical Marker Expression in Breast Carcinoma: A Tissue Microarray-based Study

Intratumoral heterogeneity in ER, PR, HER2, p53, and MIB-1 indicates their problematic interpretation in small biopsy specimens as indicative of the status of the entire tumor.

Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy

A prognostic nomogram to predict freedom from recurrence for patients treated with adjuvant hormonal therapy for localised breast cancer (BC) is developed using a Cox proportional hazards regression model.

Altered Target Gene Regulation Controlled by Estrogen Receptor-α Concentration

It is demonstrated that the concentration of receptor in breast cancer cells can influence the pattern of target gene expression through a noncanonical activation mechanism.

Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells

Elevated concentrations of estrogen and ER may provide a dual selective advantage to breast cancer cells by controlling PI-9 levels and thereby blocking immunosurveillance.



Relationship of presence of progesterone receptors to prognosis in early breast cancer.

In women with progesterone receptor-positive cancers, metastases had occurred at 18 months, in only 5% of the 39 Grade III cancers and in none of the 25 cases with invaded axillary nodes.

Prediction of relapse and survival in breast cancer patients by pS2 protein status.

It is concluded that the pS2 status of human primary breast tumors is an important variable for the identification of patients at high risk for recurrence and death.

Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.

It is demonstrated that the level of Mr 52,000 cathepsin D in cytosol of primary breast cancer biopsies is an independent prognostic factor in predicting relapses in both pre/peri- and postmenopausal patients.

Enzyme‐linked immunosorbent assay of ps2 in breast cancers, benign tumors, and normal breast tissues correlation with prognosis and adjuvant hormone therapy

The most striking correlation was observed with the outcome of adjuvant hormone therapy, pS2 concentration was shown to be the most potent prognostic factor, preceding even ER.

Multiparametric prognostic evaluation of biological factors in primary breast cancer.

A retrospective analysis has identified protease expression and tumor cell proliferation rate as important biological prognostic factors in breast cancer.

Tumour cellularity, oestrogen receptors and prognosis in breast cancer.

It is concluded that prognosis in operable breast cancer is related to oestrogen receptor activity (either per mg weight, or per cell) and to cellularity.

A simplified immuno‐enzymetric assay of the epidermal growth factor receptor in breast tumors: Evaluation in 282 cases

The data demonstrate the validity of the IEMA assay of EGF‐R in human breast tumors, which were highly correlated with the absence of estrogen receptors and/or with a high histological grade (SBR III).

Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.

The pNR-2 mRNA is regulated by oestrogens in cell lines established from metastatic human breast cancer cells. The levels of the pNR-2 and oestrogen receptor RNAs have been measured in 96 tumour

[Prognostic value of thymidine kinase in cancer of the breast].

Thymidine kinase appeared to be particularly useful in lymph-node-positive, RE-negative and grade 3 patients, and multivariate analysis of the overall survival and of the metastase free survival revealed that they were strongly related to thymidine Kinase status.